Drug Trial Radar · NCT01108783
A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine
Last checked: Nov 20, 2026Latest source record: Apr 5, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
720
Actual
Start
Apr 2003
Primary completion
Aug 2003
Study completion Feb 2004
Sponsor
- Lead sponsor
- Faes Farma, S.A.Industry
- Sponsor type
- Industry
- First posted
- Apr 22, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study was to determine the efficacy and tolerability of 20 mg of Bilastine, compared to Desloratadine and placebo for the treatment of Seasonal Allergic Rhinitis.
Conditions
- Seasonal Allergic Rhinitis
Interventions
BilastineDrug
20 mg (encapsulated) tablets QD/14 days
DesloratadineDrug
5 mg (encapsulated) tablets QD/14 days
PlaceboDrug
(encapsulated) Tablets QD/14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC of TSSTime frame: 14 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.